ALL
53
12
15
23
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.3%
6 terminated out of 53 trials
79.3%
-7.2% vs benchmark
0%
0 trials in Phase 3/4
35%
8 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (53)
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Amish/Mennonite Research Contact Registry
Venetoclax Plus Inotuzumab for B-ALL
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
A Multicenter Study of CAR-T Cells in Primary Ph+All
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Long Term Safety and Efficacy of KSM-66 Ashwagandha in Adults
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
A Long Term Follow-up Study of TScan TCR-T Products
Haplo Peripheral Blood Sct In GVHD Prevention
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Family History in a Singaporean Healthy Population
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Project Baseline Health Study